Latest news for Beroni Gr (OTC:BNIGF) Stock

Beroni Group Ltd is an Australia based company engaged in the sale of smoking control product (NicoBloc), air purifier, healthcare products and supplements, cosmetics and stem-cell therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Its operating segment includes Nicobloc, Fogibloc air purifier, Olansi water filter, Health supplements, Cosmetic products, Viral diagnostic kits, and Technical advisory service. Geographically, it operates in China and Japan. The highest revenue is generated from the Nicobloc segment through the China region.

News

Health Care

Movers & Shakers

Small Cap

Events

Global

Markets

Trading Ideas

ETFs

General

BNIGF

EMMA

LXRP

MBRX

NRIFF

ORXOY

RDHL

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

With The World In The Midst Of A Pandemic, Attention Turns To Life Sciences

Beroni Group Ltd

Rosenblatt analyst Kevin Cassidy maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and raises the price target from $70 to $75.

Price Target

Analyst Ratings

Rosenblatt Maintains Neutral on ON Semiconductor, Raises Price Target to $75

BMO Capital analyst Brian Pitz reiterates Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Outperform and maintains $92 price target.

Reiteration

UBER

BMO Capital Reiterates Outperform on Uber Technologies, Maintains $92 Price Target

Artificial intelligence progress and advertising spending are among the topics analysts and investors are eyeing when Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reports second-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Wednesday, July 31.</a>
Earnings Estimates: Analysts estimate Meta Platforms will report second-quarter revenue of $38.3 billion according to data <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073024&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company reported revenue of $32.0 billion in last year's second quarter. Meta Platforms has beaten analysts' revenue estimates in seven straight quarter sand eight of the last 10 quarters.
Analysts estimate Meta will report second-quarter earnings per share of $4.73, compared to $2.98 reported in last year's second quarter. The company beat analysts' estimates for earnings per share in five straight quarters and six of the last 10 quarters.
<a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding">Guidance from </a>Meta Platforms calls for revenue to be in a range of $36.5 billion to $39 billion.
Read Also: <a href="https://www.benzinga.com/news/24/07/40027527/mark-zuckerberg-gets-triggered-by-closed-ai-models-at-siggraph-2024-drops-f-bomb-while-talking-with">Mark Zuckerberg Drops F-Bomb While Talking With Nvidia CEO: &#8216;There Goes Our Broadcast Opportunity&#8217;</a>
What Analysts Are Saying: Investor sentiment for Meta is mixed, RBC Capital analyst Brad Erickson writes.
The analyst, who has an Outperform rating and $570 price target said the risk/reward on Meta stock is slightly favorable.
"Sentiment has been a whipsaw over the past month where we're finding more now leaning positive near term at current levels while still maintaining relative skepticism beyond the quarter," Erickson said.
Erickson said small business marketing checks show constructive advertising spending trends for the second and third quarters.
"We believe that despite a somewhat marginally softer consumer combined with evidence of worsening KPIs, advertisers continue to spend on the best digital channels which includes META."
The analyst said Meta's ad platform and new AI tools are performing well. This could lead to increased capture rates and advertising revenue.
Outside of advertising, Erickson said Meta's artificial intelligence strategy is a key from the earnings report.
"The Street will be looking for more on the bigger picture AI monetization strategy where last quarter's performance by management was more challenging."
Here are other recent<a href="https://www.benzinga.com/quote/META/analyst-ratings"> analyst ratings for Meta Platforms</a> and their price targets:
<ul>
<li>Needham: Reiterated Underperform rating, no price target</li>
<li>Benchmark: Reiterated Hold rating, no price target</li>
<li>Wedbush: Reiterated Outperform rating, $570 price target</li>
<li>Bernstein: Maintained Outperform rating, raised price target from $565 to $575</li>
<li>Oppenheimer: Maintained Outperform, raised price target from $500 to $525</li>
<li>Wolfe Research: Initiated with Outperform rating, $620 price target</li>
<li>TD Cowen: Maintained Buy rating, raised price target from $530 to $600</li>
<li>Wells Fargo: Maintained Overweight rating, raised price target from $593 to $625</li>
</ul>
Key Items to Watch: AI will likely be a key item for investors and analysts. Meta CEO Mark Zuckerberg recently unveiled<a href="https://www.benzinga.com/news/24/07/40030481/mark-zuckerberg-announces-metas-ai-studio-roll-out-at-siggraph-2024-now-create-custom-chatbots-for-y"> the rollout </a>of an AI Studio where creators can make custom AI chatbots for social media profiles.
Job cuts and spending could be another topic that could impact the stock price. In the first quarter, Meta raised its guidance for full-year 2024 expected expenses to a range of $96 billion to $99 billion. Higher infrastructure and legal costs were cited as the reason for the change from a range of $94 billion to $99 billion.
Any further raises to expenses could spook some investors away from the stock. Meta walks a cautious line of investing in future growth like its AI roadmap and also not spending too much.
Mentioned above by Erickson, advertising rates are a key for the quarter. Meta reported ad impressions were up 20% year-over-year in the first quarter with the average price per ad up 6% year-over-year. Investors will likely want to see continued momentum and year-over-year increases for both metrics.
META Price Action: Meta Platforms shares trade at $467.50 versus a 52-week trading range of $274.38 to $542.81. Meta stock is up 47% over the last year and up 32% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40028341/senate-set-to-approve-new-child-online-safety-bill-on-tuesday-what-it-means-for-elon-musks-x-meta-sn">Senate Set To Approve New Child Online Safety Bill On Tuesday: What It Means For Elon Musk&#8217;s X, Meta, Snap And TikTok</a></li>
</ul>

Analyst Color

Previews

Meta Platforms Q2 Earnings Preview: AI In Focus As 'Advertisers Spend On The Best Digital Channels — Including Meta,' Analyst Says

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading lower today. 
The company introduced its Structera line of Compute Express Link (CXL) devices, designed to address memory performance and scaling challenges in general-purpose <a href="https://www.benzinga.com/pressreleases/24/07/n40037355/marvell-introduces-breakthrough-structera-cxl-product-line-to-address-server-memory-bandwidth-and-" target="_blank" rel="noreferrer noopener">servers for cloud data centers</a>.
To tackle memory-intensive applications, data centers often add extra servers to increase memory bandwidth and capacity, which can lead to inefficiencies as additional computing power remains underutilized. The CXL industry-standard solves this by allowing new architectures to efficiently expand the memory of general-purpose servers.
Bob Wheeler, principal analyst at Wheeler&#8217;s Network stated, &#8220;Marvell has developed a long-term vision for CXL that capitalizes on this diversity of uses and will encourage hyperscalers and others to adopt CXL to scale the so-called memory wall.&#8221;
Raghib Hussain, president of products and technologies, said, &#8220;Our new Structera CXL product line will be a game-changer in enabling optimal resource utilization and lowering energy consumption for scaling memory-intensive workloads in the cloud.&#8221;
&#8220;Marvell is delivering on the promise of CXL and our commitment to customers to help them solve their most challenging issues. CXL will continue to be a critical technology enabler for accelerated infrastructure across our compute, connectivity and storage portfolios,&#8221; Hussain added.
&#8220;Marvell is an important CXL ecosystem partner to Micron, and our work together will help advance the adoption of memory expansion in the industry. Our collaboration on memory interoperability will enable flexible and scalable memory resources to match increasing processor core counts and data-intensive workloads,&#8221; said Vijay Nain, senior director of CXL Product Management at Micron. 
This week, Marvell announces the Teralynx 10 Ethernet switch device is in volume production <a target="_blank" href="https://www.benzinga.com/news/24/07/39967397/whats-going-on-with-marvell-stock" rel="noreferrer noopener">with customer deployments underway</a>.
Investors can gain exposure to the stock via Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) and Columbia ETF Trust I Columbia Seligman Semiconductor And Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMI#NYSE">SEMI</a>).
MRVL Price Action: Marvell Technologies shares are down 1.52% at $63.50 at the last check Tuesday.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39527484/marvells-new-digital-signal-processor-technology-enhances-ai-data-centers" target="_blank" rel="noreferrer noopener">Marvell&#8217;s New Digital Signal Processor Technology Enhances AI Data Centers</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Movers

Tech

MRVL

SEMI

SPRX

What's Going On With Marvell Stock Tuesday?

BMO Capital analyst Brian Pitz reiterates Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and maintains $185 price target.

TTWO

BMO Capital Reiterates Outperform on Take-Two Interactive, Maintains $185 Price Target

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) shares are trading higher by 0.64% to $148.40 during Tuesday&#8217;s session. Traders and investors are watching for the company&#8217;s first-quarter earnings report, confirmed for Tuesday&#8217;s <a href="https://www.benzinga.com/quote/EA/earnings">after-hours session</a>. According to analyst consensus estimates, EA is expected to report EPS of 43 cents on revenue of $1.286 billion.
During Electronic Arts&#8217; fourth-quarter earnings call in May, CEO Andrew Wilson announced that the development team for the upcoming Battlefield game is the largest in the franchise&#8217;s history, highlighting EA&#8217;s significant investment in its development. EA&#8217;s Motive, known for Star Wars: Squadrons and the Dead Space Remake, is working on Battlefield in addition to their current project, an Iron Man game.
Additionally, over the past three months, 16 analysts have evaluated Electronic Arts with a variety of opinions, both positive and negative. Their latest assessments highlight changes in sentiment over the past 30 days compared to previous months&#8230;<a href="https://www.benzinga.com/insights/analyst-ratings/24/07/40017884/beyond-the-numbers-16-analysts-discuss-electronic-arts-stock">Read More</a>
Read Also: <a href="https://www.benzinga.com/general/gaming/24/07/40035765/sag-aftra-calls-video-game-strike-over-ai-concerns">SAG-AFTRA Calls Video Game Strike Over AI Concerns</a>
<h2 class="wp-block-heading">Is EA A Good Stock To Buy?</h2>
When deciding whether to buy a stock, there are some key fundamentals investors may want to consider. One of these factors is revenue growth. Buying a stock is essentially a bet that the business will continue to grow and generate profits in the future.
Other important metrics to look at include a company's profitability, balance sheet, performance relative to a benchmark index and valuation compared to peers. For in-depth analysis tools and important financial data, check out <a href="https://pro.benzinga.com">Benzinga PRO</a>.
EA has a 52-week high of $150.48 and a 52-week low of $117.47.

Electronic Arts (EA) Stock Hits A New 52-Week High: What's Going On?

Contracts

European Aeronautic Defence And Space Unsponsored

EADSY

Leonardo CEO Says Back To "Rate 10" For Boeing Fuselages By 2025; In Talks With Airbus To Expand Collaboration For Rear Fuselage Of A220; Co In Negotiations With Boeing Over Slowdown Of 787 Production, Sees Positive Prospects For B787 In Long-term

WIIM

TERN

Terns Pharmaceuticals shares are trading lower after the company announced the departure of CFO Mark Vignola.

BMO Capital analyst Brian Pitz reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and maintains $56 price target.

RBLX

BMO Capital Reiterates Outperform on Roblox, Maintains $56 Price Target

<a href="https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment" title="https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment">https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment</a>.

Biotech

Guidance

AMZN

'Late Last Year, Amazon Projected Its Healthcare Businesses To Lose More Than $1B For 2024 - Business Insider Citing Internal Document

HSII

Heidrick & Struggles shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company issued Q3 net revenue guidance above estimates.

Wedbush analyst Daniel Ives maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Outperform and raises the price target from $65 to $67.

VRNS

Wedbush Maintains Outperform on Varonis Systems, Raises Price Target to $67

TRNS

Transcat shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) with a Outperform and maintains $68 price target.

CLMB

Barrington Research Maintains Outperform on Climb Global Solutions, Maintains $68 Price Target

CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares traded higher initially Tuesday morning but have since reversed following the company&#8217;s announcement that it entered into an exclusive license <a href="https://www.benzinga.com/news/24/07/40033170/cns-pharmaceuticals-expands-pipeline-with-in-license-of-late-stage-novel-potential-blood-brain-barri">agreement with Cortice Biosciences</a>.
The Details: CNS secured an exclusive license and the intellectual property rights for TPI 287, a potential treatment for glioblastoma multiforme (GBM).
CNS will pay Cortice 616, 698 shares of the company&#8217;s common stock in exchange for the license and intellectual property rights. In addition, there are possible future success-dependent milestone payments of cash or the company&#8217;s common stock&nbsp;
A multicenter Phase 1 study of TPI 287 combined with bevacizumab in recurrent GBM patients showed a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 13.4 months. In comparison, bevacizumab alone or with chemotherapy showed a PFS of 2-4 months and an OS of 6-9 months.
CNS believes that another one of its drug candidates for the treatment of GBM, Berubicin, could serve as an ideal complementary asset to TPI 287. 
John Climaco, CEO of CNS Pharmaceuticals, stated, &#8220;For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.&#8221;
The company intends to consult with the U.S. FDA to receive feedback on the design of a study aimed at registering TPI 287 for recurrent GBM, with plans to start the study in 2025. 
Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/24/07/40039420/expert-outlook-sage-therapeutics-through-the-eyes-of-14-analysts">Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts</a>
CNSP Price Action: At the time of publication, CNS shares are trading 60% lower at 41 cents, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Myriams-Fotos from Pixabay
.

CNSP

What's Going On With CNS Pharmaceuticals Stock Tuesday?

Legal

Amazon Spokesperson Says Disappointed By CPSC's Decision, Plan To Appeal Decision And Look Forward To Presenting Our Case In Court

NeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.

BWS Financial analyst Hamed Khorsand maintains Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Sell and maintains $10 price target.

BWS Financial Maintains Sell on Symbotic, Maintains $10 Price Target

Wells Fargo Sued Over Drug Costs In Employee Health Plan; Lawsuit By Former Employees Filed In Minnesota Federal Court

Cushman & Wakefield shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Beroni Gr

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.

Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus&rsquo; spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.

The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets.

&ldquo;They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping,&rdquo; he said. &ldquo;The life science business is certainly continuing.&rdquo;

In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">Virtual Life Science Investor Forum</a> on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments.

&ldquo;Certainly with what&rsquo;s going on with the coronavirus pandemic, it just makes it that much more relevant,&rdquo; said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. &ldquo;The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities.&rdquo;

According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series.

&ldquo;It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention,&rdquo; Paltrowitz said of this week&rsquo;s conference. &ldquo;And we thought being able to host a series of virtual conferences would help.&rdquo;

Below is the schedule for the conference. Each presentation is followed by a virtual Q&amp;A session with attendees and is available on demand.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

9:30 AM ET RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) 
Speaker: Guy Goldberg, Chief Business Officer 
About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill&rsquo;s recently FDA approved drug, Talicia&reg;. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.

10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NRIFF#OTCQX">NRIFF</a>) 
Speakers: Jesse Ledger, President &amp; Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer 
About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company&#39;s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.

10:30 AM ET Orexo AB (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORXOY#OTCQX">ORXOY</a>) 
Speaker: Nikolaj S&oslash;rensen, President &amp; CEO 
About: Orexo develops improved pharmaceuti&shy;cals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv&reg; for treatment of opioid use disor&shy;der.

11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQB">EMMA</a>) 
Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood 
Chief Financial Officer

About: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari&reg; (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

11:30 AM ET Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) 
Speaker: Walter Klemp, Founder, President, CEO &amp; Chairman 
About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company&#39;s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

12:00 PM ET Lexaria Bioscience Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/LXRP#OTCQX">LXRP</a>) 
Speaker: Chris Bunka, CEO 
About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH&trade; drug delivery technology changes the way API&#39;s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

12:30 PM ET Beroni Group Ltd. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BNIGF#OTCQX">BNIGF</a>) 
Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO 
About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection &amp; diagnosis of infectious diseases.

To learn more about attending Thursday&rsquo;s conference, <a href="https://www.lifesciencesinvestorforum.com/events/event-details/agenda?utm_source=Article&amp;utm_medium=Benzinga&amp;utm_campaign=LSIF%2003262020">click here</a>.

Photo by&nbsp;<a href="https://unsplash.com/@thisisengineering?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">ThisisEngineering RAEng</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/laboratory?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Beroni Gr

News

Latest news for Beroni Gr (OTC:BNIGF) Stock

Wednesday, March 25, 2020